Association of ki67 and tumor marker p53 in locally advanced breast cancer patients and evaluation of response to neoadjuvant chemotherapy: a survey in South Iran
Open Access
- 1 July 2019
- journal article
- research article
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 11, 6489-6497
Abstract
Purpose: Heterogeneity of breast cancer, the most common cancer in women, complicates approach to its treatment. Neoadjuvant chemotherapy (NAC) in the treatment of locally advanced breast cancer (LABC) with the endpoint of achieving pathologic complete response (pCR) is not always successful. The purpose of this study was to evaluate the clinicopathologic characteristics, biomarker status and response of LABCs to NAC. Patients and methods: Core biopsies and post-surgical specimens of LABC patients were evaluated after receiving NAC. Their lymph node involvement, tumor staging, grading, size, tumoral and stromal lymphocytic infiltration (TLI, SLI), hormonal status, ki67, p53 and HER2 expression were evaluated. Response to NAC was assessed using pCR, Miller-Payne grading and residual cancer burden. Results: In a total of 71 patients, pCR rate was 5.6%. Strong association was observed between ki67 positivity and p53 expression (P-value˂0.001). Also ki67, TLI and SLI showed association with triple negative tumor subtype (P-value 0.011, 0.002 and 0.014). Good response to NAC was associated with p53 expression. Nodal metastatic residue was also associated with primary tumor’s nuclear grade. Conclusion: Strong correlation of ki67 and p53 can suggest probable interchangeability of both markers in the prognosis of LABC. In this study p53 even showed superiority to ki67 having association with good response. Strong association of ki67, TLI and SLI with triple negative tumor subtype can be parallel to an overall better response rate of this subtype. We can also propose the effectiveness of defining nuclear grade as a prognostic factor towards residual lymph node involvement post NAC.Keywords
This publication has 39 references indexed in Scilit:
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Annals of Oncology, 2013
- Tumor-Associated Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Breast Cancer PatientsJournal of Breast Cancer, 2013
- Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancerBreast Cancer Research, 2011
- Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatmentBMC Cancer, 2011
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working GroupJNCI: Journal of the National Cancer Institute, 2011
- Prognostic significance of breast cancer subtype and p53 overexpression in patients with locally advanced or high-risk breast cancer treated using upfront modified radical mastectomy with or without post-mastectomy radiation therapyInternational Journal of Clinical Oncology, 2011
- Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breastBreast Cancer Research, 2008
- The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer SubtypesClinical Cancer Research, 2007
- Breast Cancer Molecular Subtypes Respond Differently to Preoperative ChemotherapyClinical Cancer Research, 2005
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001